LEADER 03159oam 22006252a 450 001 9910141437803321 005 20210114210742.0 010 $a1-118-35432-X 010 $a1-299-31459-7 010 $a1-118-35433-8 010 $a1-118-35430-3 010 $a1-118-35431-1 035 $a(CKB)2670000000231132 035 $a(EBL)875932 035 $a(OCoLC)805560505 035 $a(SSID)ssj0000694988 035 $a(PQKBManifestationID)11416226 035 $a(PQKBTitleCode)TC0000694988 035 $a(PQKBWorkID)10686134 035 $a(PQKB)10639388 035 $a(DLC) 2012008118 035 $a(MiAaPQ)EBC875932 035 $a(PPN)178867330 035 $a(EXLCZ)992670000000231132 100 $a20120224d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBiopharmaceutics modeling and simulations$b[electronic resource] $etheory, practice, methods, and applications /$fKiyohiko Sugano 210 $aHoboken, N.J. $cJohn Wiley & Sons$dc2013 215 $a1 online resource (521 p.) 300 $aDescription based upon print version of record. 311 $a1-118-02868-6 320 $aIncludes bibliographical references and index. 327 $aIntroduction -- Theoretical framework I : solubility -- Theoretical framework II : dissolution -- Theoretical framework III : biological membrane permeation -- Theoretical framework IV : gastrointestinal transit models and integration -- Physiology of gastrointestinal tract and other administration sites in humans and animals -- Drug parameters -- Validation of mechanistic models -- Bioequivalence and biopharmaceutical classification system -- Dose and particle size dependency -- Enabling formulations -- Food effect -- Biopharmaceutical modeling for miscellaneous cases -- Intestinal transporters -- Strategy in drug discovery and development -- Epistemology of biopharmaceutical modeling and good simulation practice. 330 $a A comprehensive introduction to using modeling and simulation programs in drug discovery and development Biopharmaceutical modeling has become integral to the design and development of new drugs. Influencing key aspects of the development process, including drug substance design, formulation design, and toxicological exposure assessment, biopharmaceutical modeling is now seen as the linchpin to a drug's future success. And while there are a number of commercially available software programs for drug modeling, there has not been a single resource guiding pharmaceutical professio 606 $aBiopharmaceutics$xmethods 606 $aComputer Simulation 606 $aDrug Compounding$xmethods 606 $aModels, Theoretical 615 12$aBiopharmaceutics$xmethods. 615 22$aComputer Simulation. 615 22$aDrug Compounding$xmethods. 615 22$aModels, Theoretical. 676 $a615.19 700 $aSugano$b Kiyohiko$0886431 801 0$bDLC 801 1$bDLC 801 2$bDLC 906 $aBOOK 912 $a9910141437803321 996 $aBiopharmaceutics modeling and simulations$91979516 997 $aUNINA